Medical professionals are always large proponents of preventive medicine. “Stop it before it starts,” they always say. But how do they stop a known problem when they need to perform another procedure to fix another known problem? This is a difficult answer to be sure, especially if it leaves a mark, like a scar, in a place where it would ideally not be.
Cardiovascular Sciences Inc., a medical products development company, is working toward offering product solutions for surgical adhesion issues like the one mentioned. From a laypersons perspective, an adhesion issue is the problem of tissues (skin or internal tissues) fusing together, with a scar, in a non-ideal way. If the scar is of a certain size, in a certain location or of a certain type, it can cause serious issues after the surgery or recovery period has occurred. In this sense, “serious issues” means growing back together in a way not conducive to proper body mechanics like pumping fluids or moving of joints.
Cardiovascular Sciences Inc. came to this portion of the medical products marketplace after culling the marketplace for medical products that might provide a significant and reliable revenue stream while also providing a viable medical benefit. After researching the marketplace, the company feels that its opportunity for consistent revenue and product development lies in the adhesion products marketplace.
With a solid management team and researchers in place, the company has acquired intellectual property rights for several processes. The intellectual rights obtained are considered key steps to meeting the company’s time frame of 12-18 months to the veterinary care marketplace, a marketplace chosen due to its less stringent entry requirements and reliable market size of approximately $500 million worldwide.
As veterinary markets are entered, the company plans to pursue the process of entry into the human marketplace for these types of products. Along with its University of Central Florida Research partner, the company feels confident that it will be able to garner a significant portion of the $3 billion domestic /$5 billion worldwide market for these types of products.
Given that the company has settled on this product category after researching a fairly lengthy list of possible medical sectors to develop, it is likely that focus and attention to meeting timelines will be assured. Management appears to have a fairly extensive background in the area of consideration, and surgical adhesions are not likely to become a thing of the past anytime soon. As these products are offered to the marketplace, they may well become standard operating procedure.
Let us hear your thoughts below:
